Press Releases Gilead Sciences, Inc.

Equities

GILD

US3755581036

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-02 pm EDT			5-day change	1st Jan Change
68.4 ^USD	-0.35%		-1.74%	-15.57%

Jul. 01	HOOKIPA Pharma Reports First Patient Dosed in HIV Treatment Study	MT
Jul. 01	HOOKIPA Pharma Inc. Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment of HIV	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Gilead Benefit Helps Employees Navigate Cancer Care	Jul. 01	AQ
Gilead small molecule demonstrates strong capability for HIV prevention	Jun. 21	AQ
Gilead Sciences : Access Planning in High Incidence, Resource Limited Countries for Lenacapavir for HIV Prevention	Jun. 20	PU
Gilead’s Twice-Yearly Lenacapavir Demonstrated 100% Efficacy and Superiority to Daily Truvada® for HIV Prevention	Jun. 20	BU
Gilead and Kite Pharma Celebrates Pride Month	Jun. 19	AQ
New Kite Clinical Research and Real-World Evidence for Yescarta Demonstrate Benefit from Earlier Lines of Treatment	Jun. 17	AQ
New Kite Clinical Research and Real-World Evidence for Yescarta® Demonstrate Benefit From Earlier Lines of Treatment	Jun. 14	BU
Namibian First Ladies Call for New HIV Medicine	Jun. 13	AQ
Combination therapy may hold potential for severe viral hepatitis	Jun. 06	AQ
Gilead's Seladelpar Demonstrated a Sustained and Consistent Long-Term Efficacy and Safety Profile in Primary Biliary Cholangitis	Jun. 06	AQ
Gilead Announces New England Journal of Medicine Publication of Data that Demonstrate Bulevirtide with PegIFN Achieved Post-Treatment Undetectable HDV RNA	Jun. 06	BU
Johnson & Johnson Submits Supplemental New Drug Application to U.S. FDA Seeking Expanded Pediatric Indication for HIV-1 Therapy PREZCOBIX	Jun. 05	AQ
Gilead’s Seladelpar Demonstrated a Sustained and Consistent Long-Term Efficacy and Safety Profile in Primary Biliary Cholangitis	Jun. 05	BU
Gilead Sciences : Statement on Agreement in Principle to Resolve Federal TDF Litigation	Jun. 04	PU
Kite’s Tecartus® Demonstrates Sustained Overall Survival in Adult Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia	Jun. 03	BU
Encouraging New Data Presented on Kite’s Yescarta® for Relapsed/Refractory Central Nervous System Lymphoma	Jun. 03	BU
EVOKE-01 Study Results in Metastatic NSCLC to Be Presented at an Oral Session at ASCO 2024	May. 31	BU
Gilead Provides Update on Phase 3 TROPiCS-04 Study	May. 30	BU
Cartography Announces Strategic Collaboration with Gilead to Develop Oncology Therapies against Novel Targets and Target Pairs	May. 29	AQ
Gilead to Present Latest Research Across Key Liver Disease Indications at the European Association for the Study of the Liver Congress 2024	May. 22	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Gilead Sciences, Inc.

Equities

GILD

US3755581036

Press Releases

Filters